Vnitr Lek 2024, 70(4):260-263

News in geriatric medicine - what's new in dementia?

Katarína Bielaková, Ondřej Ludka
Všeobecná interní klinika, Fakultní nemocnice Brno
Lékařská fakulta Masarykovy univerzity, Brno

Population aging is changing the world dramatically and fundamentally. Contemporary geriatrics has an interventional and preventive nature and strives to preserve physical and mental health for as long as possible, prevent loss of self-sufficiency and improve the prognosis of seniors with a focus on quality of life. Dementia is a serious problem that geriatrics deals with. The diagnosis of dementia not only affects the quality of life of individuals, but also represents a huge social and economic burden for the family, health systems and society. With the aging of the population, dementia has become an important problem in our health care and there is an urgent need to find an effective treatment.

Keywords: dementia, geriatric medicine, lecanemab, donanemab, folic acid, phototherapy.

Accepted: June 5, 2024; Published: June 20, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bielaková K, Ludka O. News in geriatric medicine - what's new in dementia? Vnitr Lek. 2024;70(4):260-263.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. World Health Organization. Dementia fact sheet. 2023. Availabler from: https://www.who.int/news-room/fact-sheets/detail/dementia
    2. Vaňková H, Hrnčiariková D, Závadová I, et al. Mezioborová klinická doporučení pro diagnostiku a léčbu Alzheimerovy nemoci: "Bílá kniha paliativní péče" v aktuálním kontextu. Geri a gero. 2024;(1):47-51.
    3. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. Demence Novelizace 2024. Availabler from: http://svl.cz/doporucene-postupy/demence-100017
    4. Kleinová L, Cerman J, Hlávka J, et al. Nové farmakologické možnosti v léčbě Alzheimerovy nemoci. Cesk Slov Neurol N. 2022;85(6):462-469. Go to original source...
    5. Hoy SM. Lecanemab: First approval. Drugs. 2023;83(4):359-365. doi: 10.1007/s40265-023-01851-2. Go to original source... Go to PubMed...
    6. Nelson S, Lopez O. Lecanemab for Alzheimer disease. Neurology. 2024; 102 (7). e209265. doi: 10.1212/WNL.0000000000209265. Go to original source... Go to PubMed...
    7. Lapka M. Lecanemab. Remedia. 2023;33:73-76. Go to original source...
    8. Eisai global. New release. March 22, 2024. Availabler from: https://www.eisai.com/news/2024/news202417.html
    9. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21. doi: 10.1056/NEJMoa2212948. Go to original source... Go to PubMed...
    10. Gueorguieva I, Willis BA, Chua L, et al. Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease. Clin Pharmacol Ther. 2023; 113(6):1258-1267. doi: 10.1002/cpt.2875. Go to original source... Go to PubMed...
    11. Lo A C, Duggan EC, Wessels AM, et al. Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384(18):1691-1704. Go to original source... Go to PubMed...
    12. The New York Times. March 8,2024. Availabler from: https://www.nytimes.com/2024/03/08/health/alzheimers-drug-donanemab.html
    13. Qiao Y, Gu J, Yu M, et al. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis. CNS Drugs. 2024 Mar;38(3):169-192. doi: 10.1007/s40263-024-01067-2. Go to original source... Go to PubMed...
    14. Ross EL, Weinberg MS, Arnold SE. Cost-effectiveness of aducanumab and donanemab for early Alzheimer disease in the US. JAMA Neurol. 2022;79(5):478-487. doi: 10.1001/jamaneurol.2022.0315. Go to original source... Go to PubMed...
    15. Nguyen HV, Mital S, Knopman DS, Alexander GC. Cost-effectiveness of lecanemab for individuals with early-stage Alzheimer disease. Neurology. 2024;102:e209218. doi: 10.1212/WNL.0000000000209218. Go to original source... Go to PubMed...
    16. Lu X, Liu C, Shao F. Phototherapy improves cognitive function in dementia: A systematic review and meta-analysis. Brain Behav. 2023 May;13(5):e2952. doi: 10.1002/brb3.2952. Go to original source... Go to PubMed...
    17. Creavin ST, Wisniewski S, Noel-Storr AH, et al. Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst Rev. 2016 Jan 13;2016(1):CD011145. doi: 10.1002/14651858.CD011145. Go to original source...
    18. Tao T, Feng G, Fang Y. Association between aspirin use and risk of dementia: a systematic review and meta-analysis. Eur Geriatr Med. 2024;15(1):3-18. doi: 10.1007/s41999-023-00877-9. Go to original source... Go to PubMed...
    19. Xu M, Zhu Y, Chen J et al. Effects of folic acid supplementation on cognitive impairment: A meta-analysis of randomized controlled trials. J Evid Based Med. 2024;17(1):134-144. doi: 10.1111/jebm.12588. Go to original source... Go to PubMed...
    20. Akhgarjand C, Vahabi Z, Shab-Bidar S, et al. The effects of probiotic supplements on oxidative stress and inflammation in subjects with mild and moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled study. Inflammopharmacology. 2024;32(2):1413-1420. doi: 10.1007/s10787-023-01427-2. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.